Publications by authors named "Taleen Haddad"
Introduction: Frailty is a robust predictor of adverse outcomes in older people. Practice guidelines recommend routine screening for frailty; however, this does not occur regularly. The Clinical Frailty Scale (CFS) is a validated, feasible instrument that can be used in a variety of clinical settings and is associated with many adverse outcomes.
View Article and Find Full Text PDFImportance: Scalable deprescribing interventions may reduce polypharmacy and the use of potentially inappropriate medications (PIMs); however, few studies have been large enough to evaluate the impact that deprescribing may have on adverse drug events (ADEs).
Objective: To evaluate the effect of an electronic deprescribing decision support tool on ADEs after hospital discharge among older adults with polypharmacy.
Design, Setting, And Participants: This was a cluster randomized clinical trial of older (≥65 years) hospitalized patients with an expected survival of more than 3 months who were admitted to 1 of 11 acute care hospitals in Canada from August 22, 2017, to January 13, 2020.
Background: Accelerated partial breast irradiation is a potential alternative to standard whole breast irradiation, following breast-conserving surgery, in the management of breast cancer. The MammoSite applicator-based technique allows for the delivery of a higher dose of radiation to the tumour bed and adjacent area, over a shorter treatment period.
Aims: To investigate the long-term feasibility of the MammoSite technique in early stage breast cancer in an Irish cohort.
Background: Downstream resource utilization and its impact on outcomes after a canceled CCTA have not been well studied. We sought to understand downstream resource utilization and patient outcomes after canceled CCTA.
Methods And Results: Consecutive patients were prospectively enrolled into an institutional cardiac CT registry.
Purpose Of Review: Since the advent of highly active antiretroviral treatment, accelerated atherosclerosis resulting in coronary artery disease (CAD) has become an area of increasing concern among patients infected with HIV. As CAD has replaced myocarditis and opportunistic infection as the most common cause of heart failure in this population, it is necessary to re-evaluate the specific risks of cardiovascular disease in HIV-infected patients taking into consideration the processes driving atherogenesis.
Recent Findings: Recent data illustrating that atazanavir is not associated with an increased risk of CAD argue against a class-wide association of protease inhibitors in HIV treatment and adverse cardiovascular outcomes.
Purpose Of Review: To discuss unresolved issues and recent findings regarding the use of statins in heart failure.
Recent Findings: Recent data from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico--Heart Failure and Controlled Rosuvastatin Multinational Trial in Heart Failure suggest that statins did not have any effect on outcome despite significant reduction in low-density lipoprotein and high sensitivity C-reactive protein.
Summary: Most of the evidence for the use of statins in heart failure originates from retrospective trials and post-hoc analyses, and is not supported by prospective randomized clinical trials.